{"article_title": "Investments in Store Remodeling Are Starting to Payoff", "article_keywords": ["remodeling", "starting", "investments", "store", "payoff"], "article_url": "http://www.forbes.com/sites/greatspeculations/2015/06/10/rite-aid-q1-sales-overview-investments-in-store-remodeling-are-starting-to-payoff/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Great Speculations", "og": {"site_name": "Forbes", "description": "Despite continued headwinds, the company exceeded its full year guidance, which it had raised after an impressive Q3. This outperformance was primarily driven by higher front-end and pharmacy sales. While a more severe flu season worked in favor of Rite Aid, it was partially offset by the launch of new generics (which being cheaper lowered the price per prescription).", "title": "Rite Aid Q1 Sales Overview: Investments in Store Remodeling Are Starting to Payoff", "url": "http://www.forbes.com/sites/greatspeculations/2015/06/10/rite-aid-q1-sales-overview-investments-in-store-remodeling-are-starting-to-payoff/", "image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "updated_time": "2015-06-10T13:42:00-04:00", "type": "article"}, "twitter": {"image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "description": "Despite continued headwinds, the company exceeded its full year guidance, which it had raised after an impressive Q3. This outperformance was primarily driven by higher front-end and pharmacy sales. While a more severe flu season worked in favor of Rite Aid, it was partially offset by the launch of new generics (which being cheaper lowered the price per prescription).", "site": "@forbes", "card": "summary_large_image", "title": "Rite Aid Q1 Sales Overview: Investments in Store Remodeling Are Starting to Payoff"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Investing,Markets,Stocks", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/investing", "section": "Investing", "modified": "2015-06-10", "published": "2015-06-10", "id": "blogAndPostId/blog/post/25-149386"}, "news_keywords": "Investing,Markets,Stocks", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "Despite continued headwinds, the company exceeded its full year guidance, which it had raised after an impressive Q3. This outperformance was primarily driven by higher front-end and pharmacy sales. While a more severe flu season worked in favor of Rite Aid, it was partially offset by the launch of new generics (which being cheaper lowered the price per prescription)."}, "_id": "\"57477af46914bd0286fd71f2\"", "article_summary": ""}